These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8296491)

  • 41. Ovarian hyperstimulation syndrome following the sole administration of injectable gonadotropin-releasing hormone agonist (triptorelin) for the pituitary down-regulation and in vitro fertilization treatment: report of two cases.
    Qublan HS; Beni-Merei Z; Megdadi M; Al-Quraan G
    Arch Gynecol Obstet; 2009 Feb; 279(2):221-3. PubMed ID: 18461341
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study.
    Cosson M; Querleu D; Donnez J; Madelenat P; Konincks P; Audebert A; Manhes H
    Fertil Steril; 2002 Apr; 77(4):684-92. PubMed ID: 11937116
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of endometriosis with leuprorelin acetate depot: a German multicentre study.
    Gerhard I; Schindler AE; Bühler K; Winkler U; Meinen K; Mancarella D; Hoffmann G; Schüssler B; Kimmig R; Kranzfelder D
    Clin Ther; 1992; 14 Suppl A():3-16. PubMed ID: 1535021
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Estrogen 'add-back' and lipid profile during GnRH agonist (triptorelin) therapy.
    Al-Omari WR; Nassir UN; Izzat B
    Int J Gynaecol Obstet; 2001 Jul; 74(1):61-2. PubMed ID: 11430944
    [No Abstract]   [Full Text] [Related]  

  • 45. Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis.
    Regidor PA; Regidor M; Schmidt M; Ruwe B; Lübben G; Förtig P; Kienle E; Schindler AE
    Gynecol Endocrinol; 2001 Jun; 15(3):202-9. PubMed ID: 11447732
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Veralipride for hot flushes during gonadotropin-releasing hormone agonist treatment.
    Vercellini P; Vendola N; Colombo A; Passadore C; Trespidi L; Crosignani PG
    Gynecol Obstet Invest; 1992; 34(2):102-4. PubMed ID: 1398260
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist.
    Steingold KA; Cedars M; Lu JK; Randle D; Judd HL; Meldrum DR
    Obstet Gynecol; 1987 Mar; 69(3 Pt 1):403-11. PubMed ID: 2950349
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Application of half-dose depot long-acting triptorelin in postoperative adjuvant therapy for endometriosis].
    Liu X; Zhang HX; Wang LP; Fu WP
    Zhonghua Yi Xue Za Zhi; 2013 Jan; 93(3):208-11. PubMed ID: 23570596
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The use of GnRH agonists in the treatment of endometriomas with or without drainage.
    Batioglu S; Celikkanat H; Ugur M; Mollamahmutoglu L; Yesilyurt H; Kundakci M
    J Pak Med Assoc; 1996 Feb; 46(2):30-2. PubMed ID: 8683844
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of endometriosis in monkeys: effectiveness of continuous infusion of a gonadotropin-releasing hormone agonist compared to treatment with a progestational steroid.
    Mann DR; Collins DC; Smith MM; Kessler MJ; Gould KG
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1277-83. PubMed ID: 3097054
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Estrogen and lipid profile in patients with endometriosis treated by GnRH agonist.
    Al-Omari WR; Nassir UN; Sulaiman WR
    Int J Gynaecol Obstet; 1999 Aug; 66(2):191-2. PubMed ID: 10468351
    [No Abstract]   [Full Text] [Related]  

  • 52. Clinical, endocrine, and metabolic effects of two doses of gestrinone in treatment of pelvic endometriosis.
    Dawood MY; Obasiolu CW; Ramos J; Khan-Dawood FS
    Am J Obstet Gynecol; 1997 Feb; 176(2):387-94. PubMed ID: 9065187
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Symptom control after different duration of triptorelin treatment following conservative surgery for deep infiltrating endometriosis: Post-hoc analysis of a multicentre, prospective, real-world study.
    Sun W; Hua K; Hong L; Zhang J; Hao M; Wang J; Zhang J; Perrot V; Li H; Zhang X
    Medicine (Baltimore); 2021 Jul; 100(30):e26753. PubMed ID: 34397719
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gonadotropin-releasing hormone agonist suppresses ovulation, menses, and endometriosis in monkeys: an individualized, intermittent regimen.
    Werlin LB; Hodgen GD
    J Clin Endocrinol Metab; 1983 Apr; 56(4):844-8. PubMed ID: 6403565
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of endometriosis with a potent agonist of gonadotropin-releasing hormone (nafarelin).
    Schriock E; Monroe SE; Henzl M; Jaffe RB
    Fertil Steril; 1985 Nov; 44(5):583-8. PubMed ID: 2932349
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Medical reversible castration with D-Trp-6-LH-RH microcapsules for the treatment of endometriosis. Preliminary results in a series of 51 patients.
    Zorn JR; Soubrane O; Siboni O; Papageorgiou G
    Contrib Gynecol Obstet; 1987; 16():254-9. PubMed ID: 2961507
    [No Abstract]   [Full Text] [Related]  

  • 57. Laparoscopic findings and hormonal patterns in the treatment of endometriosis by danazol.
    Tolino A; Romano L; Chiacchio G; Ronsini S; Montemagno U
    Acta Eur Fertil; 1987; 18(2):85-9. PubMed ID: 2957884
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Does lower dose of long-acting triptorelin maintain pituitary suppression and produce good live birth rate in long down-regulation protocol for in-vitro fertilization?
    Chen X; Feng SX; Guo PP; He YX; Liu YD; Ye DS; Chen SL
    J Huazhong Univ Sci Technolog Med Sci; 2016 Apr; 36(2):215-220. PubMed ID: 27072965
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Androgens and other hormones in buserelin therapy].
    Fuchs U; Zwirner M
    Geburtshilfe Frauenheilkd; 1991 Feb; 51(2):140-2. PubMed ID: 1904040
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pituitary desensitization for eight weeks after the administration of two distinct gonadotrophin-releasing hormone agonists.
    Matteo M; Caroppo E; Gliozheni O; Carone D; Schonauer LM; Vizziello G; Greco P; D'Amato G
    Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):77-80. PubMed ID: 16359772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.